GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financi...(nes protected 22/23 non-human pr...),Health

protected 22/23 non-human primates for over 3 1/2 years and 5/6

non-vaccinated controls died of AIDS post-AIDS virus infection.

-- GeoVax AIDS vaccines are designed to elicit protective antibodies

(Ab) as well as protective T cells (white blood cells) against the

AIDS virus. The Merck vaccine stimulates only T cells for providing

protection and does not include the Env protein of HIV which is the

target for protective antibody (Ab).

-- Protective Ab has been difficult to elicit with HIV/AIDS vaccines.

GeoVax has approached this challenge by vaccinating with the natural

form of Env (HIV envelope antigens) under conditions that elicit

tightly binding Ab. GeoVax studies in non-human primates clearly show

this Ab correlates with protection.

-- GeoVax vaccines use an attenuated smallpox vaccine to provide pulses

of HIV proteins (antigen) to stimulate protective anti-AIDS vaccine

responses. Pulses of antigen from the GeoVax vaccines elicit T cell

responses that rapidly mobilize and then contract into a state called

"central memory" from which they rapidly expand to fight the

appearance of HIV.

-- In November, GeoVax announced excellent safety and immunogenicity data

from its full-dose HIV/AIDS vaccine human trial which began in

September 2006. This full-dose trial is the second in a series of four

Phase 1 human trials designed to test the safety and immunogenicity of

the GeoVax HIV/AIDS vaccines. Involving 36 participants of which 30

received vaccine and 6 received placebo, this trial protocol included

vaccination with two full-doses of GeoVax's DNA vaccine to prime the

immune response followed by two full-doses of GeoVax's MVA vaccine to

boost the immune response. GeoVax's DNA and MVA vaccines express o
'/>"/>